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ABSTRACT 
Back ground and objectives 
 
Endotracheal intubation often gives way to airway mucosal 
traumatization resulting in post operative sore throat, cough and hoarseness 
of voice [POSTCH].These are minor sequelae after extubation but very 
distressing to the patient. Many agents have been used on the endotracheal 
tube to reduce the occurrence of POSTCH with variable results. This 
randomized controlled study was conducted to compare the incidence of 
POSTCH with betamethasone gel and lidocaine jelly as a lubricant for 
tracheal tube insertion in patients undergoing general anesthesia. 
 
Methods 
This study was conducted on three hundred American Society of 
Anaesthesiologist [ASA] class I and II patients undergoing elective general, 
orthopaedic and ear a surgeries. They were divided equally into three 
groups.100 patients [group-I], 100 patients [group II] and 100 control [group 
III].The tracheal tubes for group I were lubricated with 0.05 % 
betamethasone gel, for group II lidocaine 2% jelly was used and for control 
group III nothing was applied. A blinded anaesthesiologist interviewed all 
patients regarding POSTCH at 1,6,12 and 24 hours after surgery. 
 
Results 
The mean score for sore throat in group I was always lower than mean 
scores in group II and III at all the specified time intervals over the 24 hour 
evaluation period. The P value was < 0.05 over all the four evaluation 
periods and hence it was statistically significant. In addition, at 24 hours, the 
mean score was comparable between the groups II and III.As P value is > 
0.05, there was no statistically significant difference between group II and 
group III. The mean scores for cough was similar in group I and II at 1,6 and 
24 hours. There was no statistically significant difference between group I 
and II since the P value is >0.05.The cough was less in group I and II when 
compared to group III at 1,6 and 24 hrs but at 12 hrs there was no 
statistically significant difference between all the three groups [P value > 
0.05].The mean scores for hoarseness in group I was always lower than 
mean scores in group II and III at all the specified time intervals over the 24 
hour evaluation period. The P value was less than 0.05 over all the four 
evaluation periods and hence it was statistically significant. 
 
Interpretation and conclusion 
From the present study it can be concluded that betamethasone gel 
application on endotracheal tube significantly reduces post operative sore 
throat when compared to lidocaine jelly but the lidocaine jelly has got a 
comparable effect as betamethasone gel in reducing post operative cough 
and hoarseness of voice. 
 
Key words 
Endotracheal intubation, POSTCH, betamethasone, lidocaine. 
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INTRODUCTION 
 
Endotracheal intubation is a routine part of delivering anaesthetic gases 
and vapours to the patients undergoing surgeries. It is not without risks. Sore 
throat is the most common complaint following intubation. Cough and 
hoarseness are other problems that follow intubation. Although these are  
minor sequelae, they are very distressing to the patients. The reported value 
for post operative sore throat and hoarseness of voice ranging from 24% to 
90% even under good intubating conditions.12 
  
Different factors were identified to correlate with occurrence of these 
complications, including irritation and inflammation of the airway, 
traumatization of airway mucosa, tracheal mucosal hypoperfusion induced by 
pressure, tracheal tube contact with vocal cords, size of endotracheal tube, 
cuff design, cuff pressure and lastly duration of surgery.4,12,19 
 
Various interventions have been introduced to reduce post operative 
throat complaints, such as use of smaller size endotracheal tubes, lower intra 
cuff pressure, application of topical lidocaine, post operative inhalation of 
steroids and use of steroid coated tubes. In addition to these, post operative 
IV administration of Dexamethasone has been confirmed to offer analgesic, 
anti-inflammatory effects and also an anti emetic action. Further more this 
2 
 
intervention reduced the occurrence of severity of sore throat and hoarseness 
in patients receiving general anaesthesia with tracheal intubation.4,12 
 
In previous studies, the anti inflammatory role of steroids has been 
clearly demonstrated. Therefore, the application of betamethasone gel on the 
endotracheal tube might reduce the severity of sore throat, cough and 
hoarseness. Also, the application of local anaesthetic jelly decreases potential 
damage to the mucosa of trachea has been proved. Since the local anaesthetic 
jelly acts as a lubricant, it suppresses bucking on the endotracheal tube. 9,10 
This study aimed to evaluate the incidence of post operative sore throat, 
cough and hoarseness when betamethasone gel and lidocaine jelly were 
applied to the endotracheal tube. Hence forth, this study was conducted to 
compare the incidence of post operative sore throat, cough and hoarseness 
following application of 0.05 % betamethasone gel against 2% lidocaine jelly 
and the control groups. 
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OBJECTIVES OF THE STUDY 
 
To study the protective effects of betamethasone gel as lubricate on the 
tracheal tube in prevention of post operative sore throat, cough and 
hoarseness when compared to lidocaine jelly and without any application. 
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REVIEW OF LITERATURE 
Sore throat is a common complaint following tracheal intubation. The 
other frequent complaints are cough and hoarseness of voice. It has been 
proposed that these effects are because of irritation and inflammation of the 
airway. In addition, it has been suggested that post operative sore throat may 
be caused by the activation of tracheal pain receptors and the rapidly adapting 
stretch receptor stimulation possibly could play a role in occurrence of post 
operative cough. Furthermore, coughing during emergence from general 
anaesthesia is a serious problem that can result in potentially dangerous 
complications such as hypertension, bleeding, cardiac arrhythmias, 
myocardial ischemia, myocardial infarction, increased intracranial pressure 
and  intraocular pressure. 
 Many different studies have been conducted to evaluate the role of 
different methods in preventing these adverse effects on emergence from 
general anaesthesia. Betamethasone and lidocaine are commonly studied 
drugs and different routes of application of lidocaine have been tried In 
preventing endotracheal tube induced emergence. 
Soltani and Agadha voudi et al (2002)17 conducted a study to 
evaluate the effecti eness of various ways of lidocaine application in reducing 
post operative sore throat and cough. Two Hundred and Four ASA-PS 1 and 
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2 patients undergoing cataract surgery were selected and randomly divided 
into six groups. Group 1- 10% LIDOCAINE  was sprayed on the distal end of 
the tube and its cuff, Group 2-10 % lidocaine was sprayed on the laryngeal 
structures before intubation, Group 3-distal end of the endo tracheal tube was 
lubricated with 2 % lidocaine jelly, Group 4-1.5 mg/kg IV lidocaine 
administration at the end of surgery. Group 5-tracheal tube cuffs were 
prefilled with 2 % lidocaine and Group 6-control group.Patients with chronic 
cough and sore throat, anticipated difficult intubation,and asthma were 
excluded from the study. Induction of anaesthesia was performed with 
Alfentanil 10 mcg/kg Thiopentone Sodium 5 mg /kg and succinyl choline 1.5 
mg /kg IV to facilitate tracheal intubation. Male patients were intubated with 
8 size tracheal tubes and for female 7 size, low pressure high volume cuffed 
tubes. Maintenance of anaesthesia was performed with 50%oxygen,50 % 
N2O and Halothane 1%. After extubation, patients were evaluated for post 
operative sore throat and cough at 1 and 24 hours after surgery. 
The authors from this study concluded that the most effective methods 
to decrease post operative sorethroat and cough were intra cuff lidocaine and 
IV Lidocaine. Lubrication with 2 % lidocaine jelly was associated with 
highest frequency of cough and sore throat which was greater than that in 
control group. 
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Kori K et al (2002) conducted a study to evaluate the severity of post 
operative sore throat and hoarseness after tracheal intubation. Sixty patients 
of ASA-PS 1 and 2 status undergoing elective surgery with intubation under 
general anaesthesia. They were divided into three groups : Group 1 Lidocaine 
4 % was sprayed into the trachea, Group 2- 2 %lidocaine jelly applied over 
tracheal tube and Group 3 control. Evaluation of post operative sore throat 
was done by using Visual Analog Scale[VAS] at the end of surgery and the 
next day. 
The author concluded that Lidocaine jelly lubrication to the tracheal 
tube increases the severity of sore throat. Lidocaine sprayed to the trachea did 
not reduce post operative sore throat. 
Asif Kazemi et al (2007)3 conducted a study to evaluate the 
effectiveness of betamethasone gel in reducing sorethroat cough and 
hoarseness after laryngo tracheal intubation.One Hundred ASA-PS 1and  
2 patients aged between 16 to 50 years undergoing elective surgery under 
general anaesthesia. At entry to the operation theatre,patients were randomly 
divided into two equal groups : group A and group B.All patients were 
premedicated with 0.2 mg/kg orally.Induction of anaesthesia was performed 
with 0.2 mg/kg Morphine IV and 5 mg/kg of pentothal sodiumand 0.6 mg/kg 
of Atracurium for muscle relaxation.high volume low pressure cuffed tube of 
size 7 to 8 mm ID was selected and lubricated with 3 ml of 0.05% 
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betamethasone [group A] or KY jelly in control[ group B].Three minutes 
after injection of Atracurium intubation was done by an expert 
anaesthesiologist. Anaesthesia was maintained with 50 % oxygen and 50 % 
N2O and Halothane. At the end of surgery the trachea was extubated when 
the patient was fully awake. 
Assesment of sore throat, cough and hoarseness at 1,24 hrs after 
surgery in PACU using grading system. 
In this study, the authors recommended lubrication of all parts of 
tracheal tube that is in contact with posterior pharynx, larynx and trachea 
with betamethasone gel in order to reduce cough, hoarseness and sore throat. 
PA Sumathi et al (2008)19 conducted a study to evaluate the incidence 
of post operative sore throat, cough and hoarseness of voice by applying 
betamethasone gel and lidocaine jelly over tracheal tube in intubated patient    
using general anaesthesia. One Hundred and fifty American Society of 
Anaesthesiologist [ASA-PS] class 1 and 2 patients of either sex, aged 
between 18 to 60 yrs undergoing elective surgery under general anaesthesia 
with oro tracheal intubation. 
Patients undergoing surgeries of the oral cavity and pharynx, 
anticipated difficult airway, more than two attempts at intubation, any surgery 
lasts greater than 240 mins, use of nasogastric tube, throat packs, upper 
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respiratory tract infection and patients on steroid therapy were excluded from 
the study. 
Patients were randomly divided into three groups: Group 1 
betamethasone, Group 2 lidocaine jelly and Group 3 control [no jelly applied] 
All patients were premedicated with oral diazepam10 mg and 
ranitidine 150 mg. At induction of anaesthesia, the endotracheal tube was 
lubricated from the distal part of the cuff to a distance of 15 cm from the tip, 
using 2.5 ml of 0.055%w/w betamethasone gel or Lidocaine 2% jelly, spread 
evenly with strict aseptic precautions. High Volume Low Pressure cuffed 
poly vinyl chloride [PVC] tracheal tubes of size 7 mm and 8 mm internal 
diameter for male and female patients respectively. Induction of anaesthesia 
was done with IV Mepiridine 0.75 mg /kg and thiopentone 5 mg/kg 
.Vecuronium bromide 0.1 mg /kg was used for relaxation for tracheal 
intubation. Anaesthesia was maintained with N2O 66%, Halothane in oxygen 
0.5 to 1% along with increments of vecuronium. 
The name of the gel used was not recorded in anaesthesia chart to 
ensure that the anaesthesiologist in post anaesthesia care unit [PACU] blinded 
to the group allocation. After extubation assessment of patients for post 
operative sore throat cough and hoarseness of voice at 1,6,12 and 24 hours 
after surgery. This was carried out by PACU anaesthesiologist using the 
grading system. 
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From this study the authors concluded that betamethasone gel applied 
widely over endotracheal tube effectively mitigates post operative sore throat, 
cough and hoarseness compared with lidocaine jelly. 
Athif Akram et al (2013)4 conducted a study to compare the 
frequency of postoperative sorethroat, cough and hoarseness of voice with 
and without betamethasone gel application on endotracheal tube in intubated 
patients using general anaesthesia. One hundred American Society of 
Anaesthesiologist [ASA-PS]1 and 2 patients of either sex aged between 18 to 
60 years undergoing elective surgeries were selected and randomly divided 
equally  into two groups : betamethasone and control groups. Oro nasal 
surgeries, preoperative sore throat, anticipated difficult airway, more than one 
attempt at intubation, nasogastric tube insertion and patients on steroid 
therapy were excluded from the study. At induction, using betamethasone gel 
0.05% was applied from the distal end of the cuff to a distance of 15 cm from 
the tip, spread evenly with sterile precautions in group A and no lubrication 
in group B. All intubations were done by an expert anaesthesiologist using  
7 and 7.5 mm ID for male and female respectively. At the end of surgery, oral 
suctioning done gently just before extubation only. The trachea was 
extubated when the patient fully met the extubation criteria. All patients 
received oxygen by face mask. Assessment of sore throat, cough and 
hoarseness of voice at 6, 12 and 24 hrs after surgery using a scoring system 
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questionnaire. From this study the authors concluded that the incidence of 
sore throat, cough and hoarseness is significantly less in patients who were 
intubated with betamethasone gel lubricated tracheal tube as compared to 
control group. 
Masoomeh Tabari et al (2013) 12 conducted a study to compare the 
effectiveness of betamethasone gel applied to the tracheal tube and 
intravenous Dexamethasone on postoperative sore throat. Two Hundred and 
Twenty Five patients belonging to ASA-PS 1 and 2 aged between 20 to 45 
years d undergoing elective abdominal surgery with endotracheal intubation 
under general anaesthesia were enrolled. Patients with history of cardiac, 
respiratory, cerebrovascular disease, bronchial asthma, gastro oesophageal 
reflux, preoperative sorethroat, pre operative analgesics and anti 
inflammatory drug use and patients less than 20 yrs of age were excluded 
from the study. And also, more than two attempts at intubation,use of 
nasogastric tube or throat packs, upper respiratory infection, steroid therapy 
and pregnancy were all excluded. Pre anaesthetic evaluation was done and 
then selected patients were divided randomly into three groups with  75 
patients in each group. GROUP 1 betamethasone, Group 2 IV 
Dexamethasone and Group 3 control group. 
All patients were premedicated with IV Midazolam 40 mcg /kg.The 
routine monitoring was done with NIBP, PULSE OXIMETRY, ECG and 
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CAPNOGRAPHY. Induction was done with Fentanyl 2 mcg/kg, Propofol 2 
mcg/kg over 30 seconds followed by atracurium 0.5 mg/kg.Intubation was 
done by a single expert anaesthesiologist using a Mac intosh laryngoscope. 
The tracheal tube size 7 mm and 8 mm ID for women and men respectively. 
In both groups the maintenance of anaesthesia was done with 50 %oxygen 
and 50% N2O.Propofol 100 mcg/kg/min and Fentanyl infusion. 
The trachea was extubated after deflating the cuff when the patient was 
fully awake and all patients were received oxygen by face mask after 
extubation. assessment of post operative sore throat was done by a blinded 
anaesthesiologist using a questionnaire at 1, 6 and 24 hrs after surgery. 
The authors concluded that betamethasone gel applied over the tracheal 
tube effectively mitigates post operative sorethroat compared with IV 
Dexamethasone. 
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PHARMOCOLOGY OF BETAMETHASONE 
Betamethasone is a synthetic cortico steroid principally used to 
produce anti-inflammatory effects. It is a fluorinated derivative of 
prednisolone devoid of mineralocorticoid effect.14 
 
Chemical Name and Structure 
Its chemical name is 9-fluoro-11, 17, 21-trihydroxy-16-methylpregna-
1, 4 diene-3, 20-dione. 
 
The structural modification by placing double bond in prednisolone 
have resulted in synthetic cortico steroids with more potent gluco corticoid 
effects than their natural counter parts. 14,15 
 
 COMMERCIAL PREPARATION 
It is available as [1] Betamethasone Di Propionate 0.05%W/W and [2] 
Betamethasonctorsce Valerate 0.1% cream
BETAMETHASONE GEL 0.05%
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MECHANISM OF ACTION14 
Corticosteroids bind to high affinity cytoplasmic receptor protein leads 
to structural change in the steroid receptor complex that permits its migration 
into the nucleus and binding to glucocorticoid receptor elements which leads 
to transcription of specific m-RNA which regulates protein synthesis. The 
glucocorticoid receptor is widely distributed in all cells. Glucocorticoids 
interfere at several steps in the inflammatory response but the overall 
mechanism appears to be limitation of recruitment of inflammatory cells at 
the local site and production of pro inflammatory mediators like 
prostaglandins, leukotrienes, and PAF through inhibition of phospolipase A2. 
 
PHARMACOKINETICS14,15 
The absorption of topically applied corticosteroids depends on various 
factors such as the vehicle or delivery system used by the drug and the 
integrity of the local site. The absorption of locally applied betamethasone 
dipropionate gel is theoretically less but if it is absorbed, it follows the same 
pharmacy kinetic profile of systemic corticosteroids. It is metabolized by the 
liver and excreted primarily by the kidneys. 
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ACTIONS ON TRACHEAL MUCOSA7,8,18 
Betamethasone is a long acting glucocorticoid with potent anti-
inflammatory effect on tracheal mucosa to prevent post intubation airway 
sequelae. 
 
SIDE EFFECTS14,15 
Topical corticosteroids rarely cause serious side effects. The factors 
that increase the risk of getting side effects are potency, duration of treatment, 
the area being treated and age. The local side effects are skin atrophy, 
worsening of psoriasis, suppression of hypothalamic-pituitary-adrenal axis 
resulting in cushingoid features. These effects are more likely to occur if high 
potency corticosteroids applied over extensive areas. Steroid induced cataract 
and glaucoma can occur. 
  
 PHARMACOLOGY OF 
Lidocaine belongs to amide group of local anaesthetics which was first 
synthesized by Lofgren in 1943.It is good for both surface application as well 
as injection. Local anaesthetics are drugs that produce reversible loss of 
sensory perception, especially of pai
 
CHEMICAL NAME AND STRUCTURE
Lidocaine’s chemical name is 2
phenylacetamide]. 
COMMERCIAL PREPARATION
         It is available as a hydrochloride salt dissolved in sterile 
16 
LIDOCAINE
n in a restricted area of the body.
14,15
 
-[diethyl amino]-N
 
 
 14,15
 
-[2,6-dimethyl 
 
water or saline. 
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PHYSICOCHEMICAL PROPERTIES 
Lidocaine is freely soluble in water, the pH of 1% solution in 0.9% 
saline is 6.5 to 7.0.It is stable and can be sterilized by boiling and 
autoclaving. 
 
MECHANISM OF ACTION 
Lidocaine blocks voltage gated sodium channels from inside the cell, 
preventing subsequent channel activation and it interferes with the large 
transient sodium influx associated with membrane depolarization. As a result, 
the impulse conduction slows the rate of rise and magnitude of the action 
potential decreases. The threshold for excitation is increased until an action 
potential can no longer be produced and impulse propagation is abolished. 
 
PHARMACOKINETICS 
Less than 50 % of the drug exists in a lipid soluble non ionized form 
which is the active form at physiological pH. Absorption of Lidocaine from 
its site of administration into the systemic circulation is influenced by the 
factors such as site of administration, dosage and use of adrenaline. The 
ultimate plasma concentration of Lidocaine is determined by the rate of tissue 
distribution and the rate of clearance of the drug.  
18 
 
 
 
It is metabolized primarily by microsomal enzymes present in the liver. 
The main metabolic pathway of Lidocaine is oxidative dealkylation in the 
liver to mono ethyl glycine xylidide followed by hydrolysis of MEGX to 
xylidide. The elimination half time of lidocaine is prolonged in patients with 
liver dysfunction. The clearance is prolonged in mothers with pregnancy 
induced hypertension than normal counter parts. 
 
ACTIONS ON TRACHEAL MUCOSA9,10,11,15 
Rapidly Adapting Stretch Receptors [RARS] are found from the naso 
pharynx to bronchi are believed to be involved in the cough reflex. They are 
extremely sensitive to mechanical stimuli. By blocking these receptors 
lidocaine suppresses cough and sore throat. Another explanation proposed is 
that lidocaine suppresses the excitation of airway sensory C fibres which 
plays a role in coughing. RARS in the larynx commonly called irritant 
receptors which has very rapidly adapting response to mechanical stimuli. 
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ROUTES OF ADMINISTRATION OF LIDOCAINE FOR 
PREVENTION OF POST INTUBATION PROBLEMS20 
IV Lidocaine-the mechanism by which it suppresses cough is 
unknown. The recommended dose is 1.5 mg/kg to suppress cough reflex 
during intubation and extubation, leading to a plasma concentration of around 
3 mcg/ml. 
Topical application-Lubrication of tracheal tube with 2 % lidocaine 
jelly, 4% lidocaine spraying on larynx and trachea and lidocaine has also 
been used to fill the cuff. 
 
SYSTEMIC TOXICITY14,15 
It occurs due to an excess plasma concentration of the drug [5 to 10 
mcg/ml].Central nervous system toxicity-Numbness tongue and circumoral 
tissues, restlessness, vertigo, tinnitus, difficulty in focusing, slurred speech, 
skeletal muscle twitching most often in the face and extremities which signals 
imminence of seizures. 
Cardiovascular system toxicity-The cardiovascular system is more 
resistant to toxic effects of local anaesthetics than central nervous system. A 
concentration of greater than 5 to 10 mcg/ml may produce profound 
hypotension and also direct myocardial depression. 
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EQUIPMENT 
ENDOTRACHEAL TUBES 
The Endotracheal tube is a device that is inserted into the trachea 
through the larynx to deliver gases and vapors to and from the lungs. It is 
otherwise known as tracheal tube or tracheal catheter. 
MATERIALS OF CONSTRUCTION OF AN ENDOTRACHEAL TUBE 
The materials for constructing an endotracheal tube should possess the 
following characteristics. 14 
1. Lack of toxicity to tissues 
2. Transparency 
3. Non - inflammable 
4. Smooth, non wettable surface 
5. Allow easy passage of a suction catheter or bronchoscope. 
6. Sufficient strength in the body to prevent torsion, kinking and 
occlusion by compression 
7. Non reactivity with lubricants and anaesthetic agents 
8. Low cost and latex free. 
21 
 
 
 
Till date no material with all of the above characteristics has been 
found. 
 
VARIETIES 
Red rubber tube: 14 
 It is an age old one but still available. It can be cleaned with water, 
sterilized and reused many times. It is hard, on transparent, poor resistance to 
kinking and sticky when it gets older. It becomes clogged by inspissated 
secretions which cannot be seen since it is non transparent. Rubber allergy is 
a big concern while using red rubber tube. 
 They have low volume, high pressure cuffs which often cause post 
operative sore throat. 
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RED RUBBER ENDOTRACHEAL TUBE 
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POLY VINYL CHLORIDE [PVC] 14 
Poly vinyl chloride is the substance most widely used in making 
disposable endotracheal tubes. It is relatively inexpensive and compatible 
with tissues. It has less tendency to kink than rubber tubes and stiff enough 
for intubation at room temperature but soften at body temperature, so that 
they tend to conform to the anatomy of patient’s upper airway. It can be 
cooled to make it more firms for intubation. It has a smooth surface that 
facilitates passage of a suction catheter. Its transparency allows observation 
of respiratory moisture as well as objects in the lumen. 
 They have large volume low pressure cuffs, hence post operative 
complications are less. 
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POLY VINYL CHLORIDE [PVC]  
ENDOTRACHEAL TUBE 
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SILICONE 
Silicone is used in some tracheal tubes. It is more expensive but can be 
sterilized and reused. 
 
TUBE DESIGN 
The American Society for Testing and Materials [ASTM] and 
International Standards Organization recommendations. 14 
The internal and external walls of the tube should be circular. The 
proximal end or machine end receives the connector and it may be possible to 
shorten the tube at  this end. The distal end or the patient end is inserted into 
the trachea. It has a slanted portion called the bevel. The angle of the bevel is 
the acute angle between the bevel and the longitudinal axis of the tube. The 
opening of the bevel faces left when viewing form the concave aspect, as the 
tube is often introduced from the right and having the bevel facing the left 
facilitates visualization of the larynx as the tube is being inserted. This tube 
has a hole on the side opposite the bevel called the Murphy eye. The purpose 
of the eye is to provide an alternate pathway for gas flow if the bevel is 
occluded. A radio opaque marker is placed along the entire length of the tube 
to aid in determination of tube position after intubation. 
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TUBE SIZE 
Current standards designate tube size by the internal diameters in 
millimeters. some manufacturers also put the tube size on the pilot balloon so 
that it is easy to determine the size when the tube is inside. 14 
 
TUBE LENGTH 
The length of the tube increases as the internal diameter increases. 14,15 
 
TUBE MARKINGS 
The markings are done on the beveled side of the tube above the cuff 
and are read from lower end to machine end. 14 
 
CUFF SYSTEMS 
Cuff systems include the cuff and an inflation system. The inflation 
system consists of inflation tube, a pilot balloon and an inflation valve. The 
advantage of cuff system is to provide a seal between the tube and the 
tracheal wall. Therefore it prevents passage of pharyngeal contents into the 
trachea and also no gas leaks past the cuff during positive pressure 
ventilation. In addition, it serves to center the tube in trachea.14,15 
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CUFF 
It is an inflatable sleeve near the patient end of the tube. It is usually 
made of the same material as the tube. It should be soft, pliable and strong 
enough to resist tear. The cuff should be placed at a specified distance from 
the machine end of the tube and should not encroach on the Murphy eye. The 
cuffs are of two types: high volume low pressure and low volume high 
pressure. 14,15 
 
 
 
 
 
INFLATED CUFF IN TRACHEA 
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LOW VOLUME HIGH PRESSURE CUFF 
This type of cuff has a smaller diameter at rest and a low residual 
volume. It requires a high intra cuff pressure to achieve a seal with the 
trachea. Intra cuff pressure and lateral pressure on the tracheal wall increases 
as more air is added to the cuff. They offer better protection against 
aspiration. The most serious risk associated with high pressure cuff is 
ischemic damage to the trachea following prolonged use. 14,15 
 
HIGH VOLUME LOW PRESSURE CUFF 
A high volume low pressure cuff has a large resting volume and 
diameter and a thin compliant wall that allows a seal with the trachea to be 
achieved without stretching the wall. The main advantage in using this type is 
the risk of significant cuff induced complications following prolonged use 
might be reduced. The disadvantages are it may be difficult to insert, as the 
cuff may obscure the view and the risk of aspiration is slightly more. 14,15 
 
INFLATION SYSTEM 
Inflation lumen: This connects the inflation tube to the cuff end and it 
is located within the wall of the tracheal tube. It does not encroach on the 
tracheal tube lumen and also does not bulge forward. 14 
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EXTERNAL INFLATION TUBE 
This is external to the tube, its external diameter is less than 2.5 mm 
and is attached to the tube at a small angle. 14 
 
HEWER PILOT BALLOON 
It is attached to the external inflation tube near the inflation valve and 
gives an indication of deflation or inflation of the cuff. 14 
 
INFLATION VALVE 
It is designed so that the tip of the syringe is inserted into it, a plunger 
is displaced from it s seat and gas can be injected into the cuff. Upon removal 
of the syringe, the valve seals so that gas cannot escape from the cuff. 14    
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    HIGH VOLUME      LOW VOLUME 
 LOW PRESSURE CUFF          HIGH PRESSURE CUFF 
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CUFF AND TIP OF ENDO TRACHEAL TUBES 
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PLACEMENT OF ENDO TRACHEAL TUBE  
 
A - PROXIMAL END OF THE ENDO TRACHEAL TUBE 
B - INFLATION SYSTEM 
C - CUFF AND TIP IN TRACHEA 
D - OESOPHAGUS 
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SCORING SYSTEM FOR SORE THROAT, COUGH AND 
HOARSENESS3,4,5,12,13,16,19 
 
SORE THROAT 
0 No sore throat at any time since the operation 
1 Minimal [less than what is seen in common cold] 
2 Moderate [like what is seen in common cold] 
3 Severe [more than what is seen in common cold] 
 
COUGH 
0 No cough at any time since the operation 
1 Minimal cough or scratchy throat 
2 Moderate cough 
3 Severe cough 
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HOARSENESS 
0 No evidence of hoarseness at anytime since the operation 
 1   No evidence of hoarseness at the time of interview 
1 Hoarseness at the time of interview noted by patient only 
2 Hoarseness that is easily recognizable at the time of 
interview 
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METHODOLOGY 
A controlled comparative clinical study was conducted to evaluate the 
prevention of post operative sore throat, cough and hoarseness of voice by 
applying betamethasone gel and lidocaine jelly over endotracheal during 
general anaesthesia tube at Rajiv Gandhi Government General Hospital, 
Chennai attached to Madras Medical College after obtaining ethics 
committee clearance. 
 
Type of Study : Prospective, Randomized Control Study 
The study population consisted of three hundred American Society of 
Anaesthesiologist [ASA-PS] class 1 and 2 patients aged between 18 to 60 
years of either sex undergoing elective general, orthopaedic and ear surgeries 
with tracheal intubation under general anaesthesia. Patients undergoing 
surgeries of oral cavity and pharynx, more than a single attempt at intubation, 
anticipated difficult airway, upper respiratory tract infection, use of 
nasogastric tube or throat packs, steroid therapy, allergy to local anaesthetics 
and pregnant female were exclusion criteria. 
Pre anaesthetic assessment was done and then selected patients were 
randomly divided into three groups with 100 patients in each group. Group 1 
Betamethasone Gel 0.05% ,Group 2 Lidocaine 2% jelly and Group 3 Control 
[no jelly applied].All patients were pre -medicated with  oral Alprazolam 
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0.25 mg, Ranitidine 150 mg and Metoclopramide 10 mg 2 hours before 
surgery.NIBP,ECG,PULSE OXIMETRY monitors were connected and IV  
access established with 18 gauge venous cannula. Glycopyrrolate 0.2 mg was 
given intravenously. During induction of anaesthesia, the tracheal tube was 
lubricated from the distal tip to a distance of 17 cm proximally from the tip 
using 2.5 ml of 0.05 % betamethasone gel or 2 % lidocaine jelly, spread 
evenly with strict aseptic precautions. High volume and Low pressure cuffed 
tubes of size 8 and 7.5 mm internal diameter were used for male and female 
patients respectively. Induction of anaesthesia was performed with IV 
Fentanyl 2 mcg/kg, Thiopentone Sodium 5 mg/kg, followed by Atracurium 
0.5 mg/kg to facilitate intubation. After 3 minutes; intubation was performed 
by a single expert anaesthesiologist using Mac intosh laryngoscope. In all 
three groups, anaesthesia was maintained by 50% oxygen and 50% N2O and 
Halothane 0.5 to 0.8 %.IV Atracurium was repeated intermittently to 
maintain muscle relaxation. 
At the end of surgery,100 % oxygen was administered and residual 
neuro muscular block was reversed with 40 mcg/kg Glycpyrrolate and 50 
mcg/kg Neostigmine sulphate. Gentle oral suctioning was done just before 
extubation. The trachea was extubated after deflating the cuff when all the 
extubation criteria were met.  
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After extubation, all the patients were received 100 % by face mask. 
Assessment of post operative sore throat, cough and hoarseness of voice were 
carried out at 1,6,12 and 24 hours after surgery using grading system for 
severity of sore throat, cough and hoarseness. 
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RESULTS 
A Comparative clinical study was conducted to evaluate the prevention 
of post intubation sore throat, cough and hoarseness by lubricating 
endotracheal tube with 0.05 % betamethasone gel and Lidocaine 2% jelly in 
patients undergoing elective general, orthopaedic and ear surgeries at Rajiv 
Gandhi Government General Hospital, Chennai attached to Madras Medical 
College. 
The following observations were made during the study. 
AGE DISTRIBUTION 
The age distribution of the study population in three groups is as 
shown below. 
Table: 2 Showing age distribution 
 
Age 
(Years) * Group Crosstabulation
40 50 50 140
40.0% 50.0% 50.0% 46.7%
41 29 26 96
41.0% 29.0% 26.0% 32.0%
12 17 16 45
12.0% 17.0% 16.0% 15.0%
7 4 8 19
7.0% 4.0% 8.0% 6.3%
100 100 100 300
100.0% 100.0% 100.0% 100.0%
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
< 30 Years
30 - 40 Years
40 - 50 Years
50 - 60 Years
Age 
(Years)
Total
Group-I:
Betamethaso
ne Gel 0.05%
Group-II:
Lidocaine
Jelly 2%
Group-III:
Control (No
Jelly Applied)
Group
Total
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All the patients in group I, group II and group III were between 18 to 
60 years of age. The mean age in group I was 32.84± 11.318, in group II was 
31.29 ± 10.816 and in group III was 32.16 ± 12.595 years. There was no 
statistically significant difference between the three groups with respect to 
age [P > 0.05]. 
 
  
ANOVA
Age 
(Years)
124.927 2 62.463 .461 .631
40264.470 297 135.571
40389.397 299
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
40 
 
 
 
 
 
 
 
 
 
CHART 1 - AGE DISTRIBTUION 
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TABLE 2: SHOWING SEX DISTRIBUTION
All three groups were comparable with respect to sex of the patients 
[P value > 0.05] 
 
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
0 cells (.0%) have expected count less than 5. The
minimum expected count is 48.33.
a. 
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SEX DISTRIBUTION 
 
 
Chi-Square Tests
2.590a 2 .274
2.598 2 .273
1.277 1 .258
300
Value df
Asymp. Sig.
(2-sided)
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CHART 2 – SEX DISTRIBUTION 
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DURATION OF SURGERY 
TABLE 3 : SHOWING DURATION OF SURGERY 
 
 
 
 
 
  
Descriptives
Duration of Surgery  ( Min )
100 97.40 37.094 3.709 90.04 104.76 45 180
100 89.35 31.969 3.197 83.01 95.69 40 180
100 92.95 32.799 3.280 86.44 99.46 40 180
300 93.23 34.075 1.967 89.36 97.10 40 180
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
ANOVA
Duration of Surgery  ( Min )
3252.167 2 1626.083 1.404 .247
343911.5 297 1157.951
347163.7 299
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Post Hoc Tests 
 
 
All the surgeries in three groups took 40 to 180 minutes. The mean 
duration of surgery in group I was 97.40 ± 37.09, in group II was 89.35 ± 
31.96 and in group III was 92.95 ± 32.79.There was no statistically 
significant difference between the three groups with respect to the duration of 
surgery [P value >0.05 ]. 
  
Multiple Comparisons
Dependent Variable: Duration of Surgery  ( Min )
Tukey HSD
8.050 4.812 .217 -3.29 19.39
4.450 4.812 .625 -6.89 15.79
-8.050 4.812 .217 -19.39 3.29
-3.600 4.812 .735 -14.94 7.74
-4.450 4.812 .625 -15.79 6.89
3.600 4.812 .735 -7.74 14.94
(J) Group
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
(I) Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
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Cross tabs 
 
 
 
 
 
 
  
Duration of Surgery  ( Min ) * Group Crosstabulation
16 15 11 42
16.0% 15.0% 11.0% 14.0%
36 52 47 135
36.0% 52.0% 47.0% 45.0%
29 24 33 86
29.0% 24.0% 33.0% 28.7%
14 7 4 25
14.0% 7.0% 4.0% 8.3%
5 2 5 12
5.0% 2.0% 5.0% 4.0%
100 100 100 300
100.0% 100.0% 100.0% 100.0%
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
< 60
60 - 90
90 - 120
120 - 150
150 - 180
Duration
of Surgery 
( Min )
Total
Group-I:
Betamethaso
ne Gel 0.05%
Group-II:
Lidocaine
Jelly 2%
Group-III:
Control (No
Jelly Applied)
Group
Total
Chi-Square Tests
13.216a 8 .105
13.432 8 .098
.647 1 .421
300
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
3 cells (20.0%) have expected count less than 5. The
minimum expected count is 4.00.
a. 
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CHART 3 –DURATION OF SURGERY 
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EXTUBATION TIME 
It is the time interval between the stoppage of nitrous oxide to the time 
of extubation. 
Table 4: showing the mean extubation time in minutes. 
 
 
 
 
  
Descriptives
Extubation 
Time (Min)
100 8.167 .9996 .1000 7.968 8.365 3.5 10.5
100 11.040 1.0461 .1046 10.832 11.248 9.0 13.0
100 7.365 .8734 .0873 7.192 7.538 6.0 9.8
300 8.857 1.8556 .1071 8.646 9.068 3.5 13.0
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
ANOVA
Extubation 
Time (Min)
746.793 2 373.396 392.157 .000
282.792 297 .952
1029.585 299
Between Groups
Within Groups
Total
Sum of
Squares df Mean Square F Sig.
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Cross tabs 
 
 
 
 
  
Extubation 
Time (Min) * Group Crosstabulation
1 0 0 1
1.0% .0% .0% .3%
68 0 89 157
68.0% .0% 89.0% 52.3%
31 72 11 114
31.0% 72.0% 11.0% 38.0%
0 28 0 28
.0% 28.0% .0% 9.3%
100 100 100 300
100.0% 100.0% 100.0% 100.0%
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
Count
% within Group
< 6
6 - 9
9 - 12
> 12
Extubation 
Time (Min)
Total
Group-I:
Betamethaso
ne Gel 0.05%
Group-II:
Lidocaine
Jelly 2%
Group-III:
Control (No
Jelly Applied)
Group
Total
Chi-Square Tests
191.608a 6 .000
245.984 6 .000
4.095 1 .043
300
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
3 cells (25.0%) have expected count less than 5. The
minimum expected count is .33.
a. 
49 
 
 
 
Post Hoc Tests 
 
 
 
The mean extubation time in group I was 8.167 ± 0.999, in group II 
was 11.040 ± 1.046 and in group III was 7.365 ± 0.8734 minutes. There was 
a prolongation of extubation time in group II. As P value is < 0.05 this was 
statistically significant. 
  
Multiple Comparisons
Dependent Variable: Extubation 
Time (Min)
Tukey HSD
-2.8732* .1380 .000 -3.198 -2.548
.8018* .1380 .000 .477 1.127
2.8732* .1380 .000 2.548 3.198
3.6750* .1380 .000 3.350 4.000
-.8018* .1380 .000 -1.127 -.477
-3.6750* .1380 .000 -4.000 -3.350
(J) Group
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
(I) Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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BUCKING 
TABLE 5 : SHOWING THE BUCKING RATE. 
 
 
 
 
The percentage rate of bucking in group I was 1 %, in group II was 3% 
and in group III was 12 %. The lowest  bucking percentage was in group-I. 
As P value is <0.05 this was statistically significant. 
  
Bucking * Group Crosstabulation
1 3 12 16
1.0% 3.0% 12.0% 5.3%
99 97 88 284
99.0% 97.0% 88.0% 94.7%
100 100 100 300
100.0% 100.0% 100.0% 100.0%
Count
% within Group
Count
% within Group
Count
% within Group
Positive
Negative
Bucking
Total
Group-I:
Betamethaso
ne Gel 0.05%
Group-II:
Lidocaine
Jelly 2%
Group-III:
Control (No
Jelly Applied)
Group
Total
Chi-Square Tests
13.600a 2 .001
13.396 2 .001
11.943 1 .001
300
Pearson Chi-Square
Likelihood Ratio
Linear-by-Linear
Association
N of Valid Cases
Value df
Asymp. Sig.
(2-sided)
0 cells (.0%) have expected count less than 5. The
minimum expected count is 5.33.
a. 
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SEVERITY SCORES FOR SORE THROAT AT 1,6,12 AND 24 HOURS 
The severity of sore throat measured using grading system is shown 
below. 
 
Table 6: showing scores [0, 1, 2 and 3] for sore throat  
at different time intervals. 
 
 
Descriptives
100 .21 .456 .046 .12 .30 0 2
100 .78 .799 .080 .62 .94 0 3
100 1.53 .771 .077 1.38 1.68 0 3
300 .84 .878 .051 .74 .94 0 3
100 .17 .428 .043 .09 .25 0 2
100 1.01 .859 .086 .84 1.18 0 3
100 1.51 .759 .076 1.36 1.66 0 3
300 .90 .896 .052 .79 1.00 0 3
100 .13 .338 .034 .06 .20 0 1
100 1.04 .803 .080 .88 1.20 0 3
100 1.31 .800 .080 1.15 1.47 0 3
300 .83 .848 .049 .73 .92 0 3
100 .08 .307 .031 .02 .14 0 2
100 1.39 .920 .092 1.21 1.57 0 3
100 1.36 .835 .084 1.19 1.53 0 3
300 .94 .957 .055 .83 1.05 0 3
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Sore Throat - 1 Hour
Sore Throat - 6 Hours
Sore Throat - 12 Hours
Sore Throat - 24 Hours
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
ANOVA
87.660 2 43.830 91.248 .000
142.660 297 .480
230.320 299
91.707 2 45.853 91.961 .000
148.090 297 .499
239.797 299
76.447 2 38.223 81.943 .000
138.540 297 .466
214.987 299
111.847 2 55.923 102.406 .000
162.190 297 .546
274.037 299
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Sore Throat - 1 Hour
Sore Throat - 6 Hours
Sore Throat - 12 Hours
Sore Throat - 24 Hours
Sum of
Squares df Mean Square F Sig.
54 
 
 
 
 
Post Hoc Tests 
 
 
 
  
Multiple Comparisons
Tukey HSD
-.570* .098 .000 -.80 -.34
-1.320* .098 .000 -1.55 -1.09
.570* .098 .000 .34 .80
-.750* .098 .000 -.98 -.52
1.320* .098 .000 1.09 1.55
.750* .098 .000 .52 .98
-.840* .100 .000 -1.08 -.60
-1.340* .100 .000 -1.58 -1.10
.840* .100 .000 .60 1.08
-.500* .100 .000 -.74 -.26
1.340* .100 .000 1.10 1.58
.500* .100 .000 .26 .74
-.910* .097 .000 -1.14 -.68
-1.180* .097 .000 -1.41 -.95
.910* .097 .000 .68 1.14
-.270* .097 .015 -.50 -.04
1.180* .097 .000 .95 1.41
.270* .097 .015 .04 .50
-1.310* .105 .000 -1.56 -1.06
-1.280* .105 .000 -1.53 -1.03
1.310* .105 .000 1.06 1.56
.030 .105 .956 -.22 .28
1.280* .105 .000 1.03 1.53
-.030 .105 .956 -.28 .22
(J) Group
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
(I) Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Dependent Variable
Sore Throat - 1 Hour
Sore Throat - 6 Hours
Sore Throat - 12 Hours
Sore Throat - 24 Hours
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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NPar Tests 
Kruskal-Wallis Test 
 
 
 
 
Ranks
100 87.78
100 147.00
100 216.73
300
100 79.23
100 162.71
100 209.57
300
100 80.08
100 173.38
100 198.04
300
100 69.94
100 190.76
100 190.81
300
Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Sore Throat - 1 Hour
Sore Throat - 6 Hours
Sore Throat - 12 Hours
Sore Throat - 24 Hours
N Mean Rank
Test Statisticsa,b
127.401 131.189 117.940 145.116
2 2 2 2
.000 .000 .000 .000
Chi-Square
df
Asymp. Sig.
Sore Throat
- 1 Hour
Sore Throat
- 6 Hours
Sore Throat
- 12 Hours
Sore Throat
- 24 Hours
Kruskal Wallis Testa. 
Grouping Variable: Groupb. 
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The mean scores for sore throat in group I was always lower than mean 
scores in group II and III at all the specified time intervals over the 24 hr 
evaluation period. The P value was <0.05 over all the four evaluation periods 
and hence it was statistically significant. In addition, at 24 hrs, the mean score 
is comparable between the groups II and III.  As P value is > 0.05, hence 
there was no statistically significant difference between group II and III. 
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CHART 6 – MEAN SCORES FOR SORE THROAT 
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SEVERITY SCORES FOR COUGH AT 1,6,12 AND 24 HOURS 
Table 7: showing the scores for cough at different time intervals. 
 
 
 
 
 
  
Descriptives
100 .31 .598 .060 .19 .43 0 2
100 .27 .548 .055 .16 .38 0 2
100 .60 .696 .070 .46 .74 0 2
300 .39 .632 .037 .32 .47 0 2
100 .19 .443 .044 .10 .28 0 2
100 .17 .428 .043 .09 .25 0 2
100 .38 .582 .058 .26 .50 0 2
300 .25 .497 .029 .19 .30 0 2
100 .19 .506 .051 .09 .29 0 2
100 .15 .411 .041 .07 .23 0 2
100 .25 .435 .044 .16 .34 0 1
300 .20 .453 .026 .15 .25 0 2
100 .16 .420 .042 .08 .24 0 2
100 .09 .288 .029 .03 .15 0 1
100 .27 .468 .047 .18 .36 0 2
300 .17 .405 .023 .13 .22 0 2
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Cough - 1 Hour
Cough - 6 Hours
Cough - 12 Hours
Cough - 24 Hours
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
ANOVA
6.487 2 3.243 8.517 .000
113.100 297 .381
119.587 299
2.687 2 1.343 5.615 .004
71.060 297 .239
73.747 299
.507 2 .253 1.236 .292
60.890 297 .205
61.397 299
1.647 2 .823 5.165 .006
47.340 297 .159
48.987 299
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Cough - 1 Hour
Cough - 6 Hours
Cough - 12 Hours
Cough - 24 Hours
Sum of
Squares df Mean Square F Sig.
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Post Hoc Tests 
 
 
 
  
Multiple Comparisons
Tukey HSD
.040 .087 .891 -.17 .25
-.290* .087 .003 -.50 -.08
-.040 .087 .891 -.25 .17
-.330* .087 .001 -.54 -.12
.290* .087 .003 .08 .50
.330* .087 .001 .12 .54
.020 .069 .955 -.14 .18
-.190* .069 .018 -.35 -.03
-.020 .069 .955 -.18 .14
-.210* .069 .007 -.37 -.05
.190* .069 .018 .03 .35
.210* .069 .007 .05 .37
.040 .064 .807 -.11 .19
-.060 .064 .617 -.21 .09
-.040 .064 .807 -.19 .11
-.100 .064 .264 -.25 .05
.060 .064 .617 -.09 .21
.100 .064 .264 -.05 .25
.070 .056 .431 -.06 .20
-.110 .056 .127 -.24 .02
-.070 .056 .431 -.20 .06
-.180* .056 .005 -.31 -.05
.110 .056 .127 -.02 .24
.180* .056 .005 .05 .31
(J) Group
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
(I) Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Dependent Variable
Cough - 1 Hour
Cough - 6 Hours
Cough - 12 Hours
Cough - 24 Hours
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
60 
 
NPar Tests 
Kruskal-Wallis Test 
 
 
The mean scores for cough was similar in group I and II  at 1,6 and 24 
hours.There is no statistically significant difference between group I and II 
since the P value is > 0.05. The incidence of cough was less in groups I and II 
compared to group III  at 1,6 and 24 hrs but at 12 hours,there was no 
statistically significant difference between all the three groups [P value 
>0.05] 
Ranks
100 139.91
100 136.21
100 175.38
300
100 143.39
100 140.48
100 167.64
300
100 146.31
100 144.07
100 161.13
300
100 147.28
100 139.37
100 164.86
300
Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Cough - 1 Hour
Cough - 6 Hours
Cough - 12 Hours
Cough - 24 Hours
N Mean Rank
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CHART 7  
MEAN SCOES FOR COUGH 
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SEVERITY SCORES FOR HOARSENESS AT 1,6,12 AND 24 HOURS 
Table 8: showing the scores for hoarseness at different intervals 
 
 
 
Descriptives
100 .13 .393 .039 .05 .21 0 2
100 .30 .503 .050 .20 .40 0 2
100 .50 .674 .067 .37 .63 0 2
300 .31 .555 .032 .25 .37 0 2
100 .16 .420 .042 .08 .24 0 2
100 .32 .510 .051 .22 .42 0 2
100 .52 .674 .067 .39 .65 0 2
300 .33 .563 .032 .27 .40 0 2
100 .08 .273 .027 .03 .13 0 1
100 .32 .469 .047 .23 .41 0 1
100 .59 .698 .070 .45 .73 0 2
300 .33 .550 .032 .27 .39 0 2
100 .06 .239 .024 .01 .11 0 1
100 .27 .468 .047 .18 .36 0 2
100 .42 .496 .050 .32 .52 0 1
300 .25 .441 .025 .20 .30 0 2
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Hoarseness - 1 Hour
Hoarseness - 6 Hours
Hoarseness - 12 Hours
Hoarseness - 24 Hours
N Mean Std. Deviation Std. Error Lower Bound Upper Bound
95% Confidence Interval for
Mean
Minimum Maximum
ANOVA
6.860 2 3.430 11.941 .000
85.310 297 .287
92.170 299
6.507 2 3.253 10.960 .000
88.160 297 .297
94.667 299
13.020 2 6.510 25.009 .000
77.310 297 .260
90.330 299
6.540 2 3.270 18.781 .000
51.710 297 .174
58.250 299
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Between Groups
Within Groups
Total
Hoarseness - 1 Hour
Hoarseness - 6 Hours
Hoarseness - 12 Hours
Hoarseness - 24 Hours
Sum of
Squares df Mean Square F Sig.
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Post Hoc Tests 
 
 
  
Multiple Comparisons
Tukey HSD
-.170 .076 .066 -.35 .01
-.370* .076 .000 -.55 -.19
.170 .076 .066 -.01 .35
-.200* .076 .024 -.38 -.02
.370* .076 .000 .19 .55
.200* .076 .024 .02 .38
-.160 .077 .096 -.34 .02
-.360* .077 .000 -.54 -.18
.160 .077 .096 -.02 .34
-.200* .077 .027 -.38 -.02
.360* .077 .000 .18 .54
.200* .077 .027 .02 .38
-.240* .072 .003 -.41 -.07
-.510* .072 .000 -.68 -.34
.240* .072 .003 .07 .41
-.270* .072 .001 -.44 -.10
.510* .072 .000 .34 .68
.270* .072 .001 .10 .44
-.210* .059 .001 -.35 -.07
-.360* .059 .000 -.50 -.22
.210* .059 .001 .07 .35
-.150* .059 .031 -.29 -.01
.360* .059 .000 .22 .50
.150* .059 .031 .01 .29
(J) Group
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
(I) Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Dependent Variable
Hoarseness - 1 Hour
Hoarseness - 6 Hours
Hoarseness - 12 Hours
Hoarseness - 24 Hours
Mean
Difference
(I-J) Std. Error Sig. Lower Bound Upper Bound
95% Confidence Interval
The mean difference is significant at the .05 level.*. 
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NPar Tests 
Kruskal-Wallis Test 
 
  
Ranks
100 127.52
100 151.83
100 172.15
300
100 128.38
100 151.26
100 171.86
300
100 118.52
100 153.08
100 179.90
300
100 122.47
100 152.74
100 176.29
300
Group
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Group-I: Betamethasone
Gel 0.05%
Group-II: Lidocaine Jelly
2%
Group-III: Control (No
Jelly Applied)
Total
Hoarseness - 1 Hour
Hoarseness - 6 Hours
Hoarseness - 12 Hours
Hoarseness - 24 Hours
N Mean Rank
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The mean scores for hoarseness in group I was always lower than 
mean scores in group II and III at all the specified time intervals over the 24 
hour evaluation period. The P value was less than 0.05 over all the four 
evaluation periods and hence it was statistically significant. 
  
Test Statisticsa,b
22.493 20.178 40.175 34.667
2 2 2 2
.000 .000 .000 .000
Chi-Square
df
Asymp. Sig.
Hoarseness -
1 Hour
Hoarseness -
6 Hours
Hoarseness -
12 Hours
Hoarseness -
24 Hours
Kruskal Wallis Testa. 
Grouping Variable: Groupb. 
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CHART 8   
MEAN SCORES FOR HOARSE NESS OF VOICE 
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DISCUSSION 
Endo tracheal intubation is the placement of a flexible tube into the 
trachea to maintain an open airway or acts as a conduit through which to 
administer anaesthetic gases and vapours. The main indications for tracheal 
intubation are: 15                                                           
1. Air way protection  
2. Maintenance of patent airway  
3. Application of positive pressure ventilation  
4. Pulmonary toileting and  
5. Maintenance of adequate level of oxygenation. 
Endo tracheal tubes are classified into cuffed and uncuffed. cuffed 
tracheal tubes are commonly used to facilitate positive pressure ventilation 
and protect from aspiration into airway. Again cuffed tubes are divided into 
low volume high pressure cuffed and high volume low pressure cuffed tubes. 
High pressure cuffed tubes are associated with potential ischemic damage to 
the tracheal mucosa therefore it is unsuitable for prolonged duration of 
intubation and ventilation. Low pressure cuffs might have a large contact 
surface area with the tracheal mucosa which predispose to higher incidence 
of sore throat, spontaneous extubation and difficult insertion because of the 
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floppy cuff. None the less, low pressure cuffs are commonly recommended 
because of lower risk of mucosal damage to tracheal mucosa. 15,16 
The most frequent side effect of intubation is sore throat with a 
reported incidence ranging from 24% to 90% The important factors which 
affect the incidence of post intubation sore throat are irritation and 
inflammation of the airway, trauma to the airway mucosa, cuff design, cuff 
pressure, tube size and lubricants used. The other common side effects are 
post operative cough and hoarseness of voice. Although the exact patho 
physiologic mechanism responsible for post intubation throat complaints are 
not elucidated, mucosal damage to the trachea and pressure induced tracheal 
mucosal capillary hypo perfusion are thought to be the causative factors for 
tracheal morbidity. 1,9,10,12 
Coughing during emergence from general anaesthesia is a big concern 
and the goal of an anaesthesiologist should be smooth emergence with 
minimal coughing. Coughing during emergence probably results from 
irritation of the respiratory mucosa by the endotracheal tube and its cuff. 
Coughing could result in sore throat, tachycardia, increased BP, arrhythmias 
and precipitation of myocardial ischemia in patients with coronary artery 
disease. It also causes increased intra thoracic, intra abdominal pressure with 
consequent increase in venous pressure which in turn leads to increased 
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bleeding from wound site, increased intra cranial and intra ocular pressure. 
1,9,10,11,19
 
Hoarseness is an another problem which makes the patient distressed. 
It indicates some amount of vocal cord injury because of tracheal tube size. 
However it has been proposed that post operative sore throat may be caused 
by the activation of tracheal pain receptors and coughing on emergence and 
in the post extubation period are thought to be due to stimulation of irritant 
rapidly adapting stretch receptors in the trachea and larynx. Blocking of these 
receptors can decrease the post operative sore throat, cough and other post 
intubation problems. 
Many interventions were applied to prevent POSTCH such as use of 
smaller size tracheal tubes, lower pressure in the cuffs, application of topical 
lidocaine,IV administration of lidocaine and inhalational of steroids post 
operatively. More recently post operative administration of IV 
dexamethasone has shown beneficial analgesic, anti inflammatory and anti 
emetic actions.Its prophylactic use significantly decreased the incidence of 
sore throat after extubation. 2,12,19 
It is clear to understand the anti inflammatory role of steroids from 
previous studies. Therefore the application of betamethasone gel to the 
tracheal tube might reduce the incidence of post operative sore throat, cough 
and hoarseness of voice. It has been proved that application of local 
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anaesthetic jelly limits potential damage to the tracheal mucosa because it 
suppresses bucking on the tracheal tube. Previous small studies were done to 
evaluate the effectiveness of betamethasone gel and lidocaine jelly in 
preventing POSTCH. 2,4,12,19 
This study was conducted to compare the incidence of POSTCH 
following application of betamethasone gel to the tracheal tube against 
lidocaine jelly and control groups in a randomized controlled study. The 
demographic profile of the patients was similar in all three groups. There was 
no difference between the three groups with respect to the type of surgery, 
duration of surgery and the anaesthetic management. 
In this study, a high volume low pressure cuff tube was used in order to 
avoid tracheal mucosal ischemic damage caused by high pressure cuff. P.A. 
Sumathi, Asif kazemi, Masoomeh tabari, Athif Akram, Ayoub and Dhanpal 
were also used low pressure cuffed tracheal tubes made of poly vinyl 
chloride. In the present study,2.5 ml  of  0.05 %betamethasone and 2 
%lidocaine jelly were used to lubricate the endotracheal tube from the lower 
part of the cuff  to a distance of 17 cm from the tip proximally in order to 
cover the contact area of the tube with trachea,larynx,vocalcords and 
oropharyngeal structures. P.A.Sumathi et al used 2.5 ml of 0.05 % 
betamethasone and 2% lidocaine to apply on the tracheal tube from the lower 
part of the cuff to 15 cm from the tip proximally.Tabari et al  applied 0.05 % 
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betamethasone  to all portions of the endotracheal tube that come into contact 
with post pharyngeal structures, vocal cords and trachea not just to the tip and 
cuff of the tracheal tube.Akram and Kazemi were used 2.5 ml of 
betamethasone gel to lubricate from the tip to the level of 15 cm 
upwards.Ayoub utilized 2.5 ml of betamethasone to apply from the lower 
portion of the cuff to a level of 15 cm upwards from the same. Stride in his 
study applied 1% Hydrocortisone cream from the tip to 5 cm above the cuff. 
Already proven fact is that wide spread steroid application over endotracheal 
tube reduces post operative throat morbidities. 3,4,5,12,18,19 
EXTUBATION TIME 
The time duration between the stoppage of nitrous oxide to the time of 
extubation in minutes. In the present study, the mean extubation time was 
7.36 minutes in the control group, in lidocaine jelly group it was 11.04 
minutes and in betametasone gel group it was 8.16 minutes. The prolongation 
of the extubation time in the lidocaine jelly group was due to a markedly 
improved tolerance of the tracheal tube. 
BUCKING 
The occurrence of bucking on the endotracheal tube at extubation was 
observed and recorded in all three groups. The rate of bucking was less in 
betamethasone group compared to lidocaine and control groups. Out of 100 
cases only one patient had bucking in betametasone group, three in lidocaine 
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and 12 in control group. From this, it was clear that betamethasone reduced 
bucking at extubation when compared to lidocaine and control groups. The 
previous studies done by P.A.sumathi, Tabari, Akram and Kazemi did not 
include bucking at extubation.In this present study, bucking on extubation is 
included since it causes damage to the tracheal mucosa which in turn 
contributes to post operative throat problems. 3,4,12,15 
SORE THROAT 
In the present study, we assessed sore throat at different time intervals 
from 1 hour after extubation up to 24 hours using scoring system 
questionnaire for sore throat. The mean scores for sore throat in 
betamethasone group at 1hr 0.21,6 hours 0.17,12 hours 0.13 and 24 hrs 0.08 
whereas in lidocaine group  0.78,1.01,1.04 and 1.39 at 1,6,12 and 24 hrs 
respectively. The occurrence of sore throat was higher in control group. 
There was a significant decrease in the mean scores for sore throat in the 
betamethasone group at all the time intervals i.e; 1,6,12 and 24 hours 
compared to lidocaine and control groups [P value <0.05], indicating a 
decrease in the severity of post operative sore throat in the betamethasone 
group. An interesting finding was observed that sore throat at 24 hours was 
comparable between lidocaine and control group. As P value is > 0.05, hence 
it was not statistically significant. P.A.Sumathi 19 found that there was a 
decrease in severity of sore throat, cough and hoarseness in betamethasone 
73 
 
group than in lidocaine and control groups at 1,6,12 and 24 hrs [P value > 
0.05].  
COUGH 
In this study the mean scores for cough was similar and comparable 
between betamethasone and lidocaine groups at 1,6,12 and 24 hours. There 
was no statistically significant difference between betamethasone and 
lignocaine groups with respect to cough[P value > 0.05].At 12 hours there 
was no significant difference between all three groups [P > 0.05]. 
HOARSENESS 
The mean score for hoarseness in group I was less when compared to 
lidocaine and control groups at 1, 12 and 24 hours. There was a statistically 
significant difference between betamethasone and other groups [P value 
>0.05].It was concluded that betamethasone gel reduced post operative 
hoarseness significantly when compared to lidocaine jelly except at 6 hours. 
The positive finding of this study is that the application of 
betamethasone gel is effective in decreasing the occurrence and severity of 
post operative sore throat, cough and hoarseness. Previous studies by  
Asif Kazemi 3 compared use of betamethasone gel with control group. They 
found that the beneficial effects of betamethasone when used to lubricate the 
tube that come into having a contact with trachea, larynx, vocal cords and 
posterior pharynx. Sumathi et al compared betamethasone against lidocaine 
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and control group. They concluded that the use of betamethasone to lubricate 
the endotracheal tube effectively decreases sore throat, cough and hoarseness 
after operation. 19 However, in this study, the bucking at extubation was not 
recorded. Our study results confirmed the observations made by previous 
authors. We had designed a different study by enrolling a larger sample of 
participants and control group is also added. This study has allowed to 
consider extubation protocol and recorded the occurrence of bucking on tube 
at extubation.Our findings showed lower rate of bucking at extubation in 
betamethasone group compared to lidocaine and control group. The dose of 
betamethasone gel used in this study was equivalent to 4 mg of prednisolone 
and that of lidocaine jelly was 50 mg, which is in the safe clinical range for 
both drugs. Though there was a concern that the possibility of flaring up of 
infection with topical steroid application, there were no reports of adverse 
effects secondary to betamethasone gel application on endotracheal tube. The 
drawbacks in the present study are that intra cuff pressure monitoring was not 
done and the correlation between bucking and severity of postoperative throat 
morbidities could not be made out.  
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CONCLUSION 
 
From the present study, it can be concluded that betamethasone gel 
application on endotracheal tube significantly reduces post operative sore 
throat when compared to lidocaine jelly but the lidocaine jelly has got a 
comparable effect as betamethasone gel in reducing postoperative cough and 
hoarseness of voice. 
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SUMMARY 
 
The present study entitled ״A prospective randomized controlled study 
to compare the application of betamethasone gel and lidocaine jelly on 
tracheal tube to reduce post operative sore throat, cough and hoarseness of 
voice˝ was carried out at Rajiv Gandhi government general hospital ,attached 
to Madras Medical College, Chennai after obtaining ethics committee 
clearance. 
 
The study population consisted of 300 patients aged between 18 to 60 
years of either sex undergoing elective general, orthopaedic and ear surgeries 
divided into three groups of 100 each. 
 
Group I Betamethasone gel 0.05%, Group II Lidocaine 2% jelly and 
Group III Control [no jelly applied].  
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TABLE 9  
SUMMARY OF THE STUDY 
 
PARTICULARS GROUP I GROUP II GROUP III 
Mean age [yrs] 32.84± 11.31 31.29± 10.81 32.16 ±11.49 
Male: Female 50:50 47:53 58:42 
Mean duration  
of surgery 
97.40 ±37.0 89.35 ±31.9 92.95±32.7 
Mean extubation  
time [min] 
8.16 ±0.99 11.04±1.04 
7.36±0.87 
 
 
 
Mean scores for Sore throat 
1 Hour 0.21±0.45 0.78 ±0.79 1.53±0.77 
6 Hours 0.17 ±0.42 1.01±0.85 1.51±0.75 
12 Hours 0.13 ±0.33 1.04 ±0.80 1.31±0.80 
24 Hours 0.08 ±0.30 1.39 ±0.92 1.36±0.83 
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COUGH 
PARTICULARS GROUP I GROUP II GROUP III 
1 Hour 0.31±0.59 0.27±0.54 0.60±0.69 
6 Hours 0.19±0.44 0.17±0.42 0.38±0.58 
12 Hours 0.19±0.50 0.15±0.41 0.25±0.43 
24 Hours 0.16±0.42 0.09±0.28 0.27±0.46 
 
                                     
HOARSENESS                              
PARTICULARS GROUP I GROUP II GROUP III 
1 Hour 0.13±0.39 0.30±0.50 0.50±0.674 
6 Hours 0.16±0.42 0.32±0.51 0.52±0.67 
12 Hours 0.08±0.27 0.32±0.46 0.59±0.69 
24 Hours 0.06±0.23 0.27±0.46 0.42±0.49 
 
In conclusion, application of 0.05% betamethasone gel results in a 
significant decrease in post operative sore throat when compared to lidocaine 
jelly but the lidocaine jelly has got a comparable effect as betamethasone in 
reducing cough and hoarseness of voice. 
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ANNEXURES 
  
PROFORMA 
A prospective randomized control study to compare the application of 
betamethasone gel  and lidocaine jelly on tracheal tube to reduce post 
operative sore throat, cough and hoarseness of voice. 
 
Name:                                  Age:                       Sex:           I.P No                  
Unit      
 
Date of surgery                                                     weight 
 
Pre operative diagnosis:                     
 
Proposed surgery 
 
Surgery done 
 
 
Duration of surgery 
 
Surgery started at:                                                  Ended at 
 
PRE ANAESTHETIC EVALUATION 
 
History 
 
General physical examination 
 
Systemic examination 
 
Cardio respiratory system                                                 Respiratory system 
 
Pulse Rate                                                                        Blood Pressure 
 
Airway                                                                              Neck and Spine 
 
ASA PHYSICAL STATUS 
 
ANAESTHETIC MANAGEMENT 
 
Pre medication                                     Oral Alprazolam 0.25 mg, Ranitidine 
150 mg, Metoclopramide 10 mg 
 
Induction                                             Inj.Fentanyl 2 mcg /kg,   
Inj.Thiopentone 5 mg/kg, Inj.Atracurium 0.5 mg /kg 
 
Attempts taken for intubation                   
 
Size of the tracheal tube used 
 
Maintenance:                50 % nitrous oxide, 50 % oxygen and Halothane 0.8% 
 
Nitrous cut off time 
 
Reversal                                               Inj.Neostigmine and Inj.Glycopyrrolate 
 
Extubation time 
 
SCORING FOR SORE THROAT COUGH AND HOARSENESS 
 
                                    SORE THROAT             COUGH                      
HOARSENESS 
1 HR 
 
6 HRS 
 
12 HRS 
 
24 HRS    
  
  
  
 
 
 
 
 
 
TURNITIN PLAGIARISM SCREEN SHOT 
 
 
 
 
  
   
INFORMATION SHEET 
 
Investigator :  
Name of the Participant: 
Title: “A Prospective, randomized controlled study to compare 
application of betamethasone gel and lidocaine jelly over tracheal tube to 
reduce post operative sore throat , cough and hoarseness of voice”. 
You are invited to take part in this research study. We have got 
approval from the IEC. Your are asked to participate because you satisfy the 
eligibility criteria. We want to compare application of betamethasone gel and 
lidocaine jelly over tracheal tube to reduce post operative sore throat, cough 
and hoarseness of voice after general tracheal anaesthesia 
 
What is the Purpose of the Research: 
 In this study is done  to compare the  application of betamethasone 
gel, lidocaine jelly  over tracheal tube with control group after general 
anaesthesia in respect to incidence of,  
 1. Sorethroat  
 2. Cough 
 3. Hoarseness of voice 
The Study Design: 
        All the patients in the study will be divided into two groups. 
Group 1-Betamethasone gel. 
Group 2-Lidocaine jelly. 
Group 3-Control 
Benefits 
Expected reduction in severity of sore throat , cough , hoarseness of 
voice after application of betamethasone and lignocaine jelly over tracheal 
tube which leads to subjective feeling of relief from distress 
 
Risks 
            Although flaring up of local subtle infection is a possibility with 
topical steroid application , there are no reports of adverse effects secondary 
to betamethasone gel application over tracheal tube.       
This intervention has been shown to be well tolerated as shown by 
previous studies. And if you do not want to participate you will have 
alternative of setting the standard treatment and your safety is our prime 
concern. 
Time :                                                                     
Date : 
Place : 
Signature / Thumb Impression of Patient 
Patient Name: 
 
Signature of the Investigator : ____________________________ 
 
Name of the Investigator : ____________________________ 
PATIENT CONSENT FORM 
Study title  :  “A Prospective,   randomized controlled study to compare application of 
betamethasone gel and lidocaine jelly over tracheal tube to reduce post operative sore 
throat , cough and hoarseness of voice”. 
 
Study center:       
INSTITUTE OF ANAESTHESIOLOGY AND CRITICAL CARE, 
            RAJIV  GANDHI GOVT. GENERAL HOSPITAL,  
            MADRAS MEDICAL COLLEGE, 
            CHENNAI 3. 
 
Participant name :                                                Age:                         Sex:                                
I.P.No: 
 
I confirm that I have understood the purpose of procedure for the above study . I 
have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction. 
I have been explained about the pitfall in the procedure.  I have been explained 
about the safety, advantage and disadvantage of the technique. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at anytime without giving any reason. 
            I understand that investigator ,regulatory authorities and the ethics committee will 
not need my permission to look at my health records both in respect to current study and 
any further research that may be conducted in relation to it, even if I withdraw from the 
study . I understand that my identity will not be revealed in any information released to 
third parties or published , unless as required under the law . I agree not to restrict the use 
of any data or results that arise from the study . 
Time:          
Date:      Signature / thumb impression of patient  
Place:                                                               Patient name: 
Signature of the investigator:   Name of the investigator: 
 KEY TO MASTER CHART 
 
I.P. NO  =  In patient number 
 
M   =  Male 
 
F   =  Female 
 
+   =  present 
 
_   =  absent 
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